These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24687742)

  • 21. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Zhang XH; Shin JY; Kim JO; Oh JE; Yoon SA; Jung CK; Kang JH
    Cancer Lett; 2012 Sep; 322(2):213-22. PubMed ID: 22433711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
    Honore S; Kamath K; Braguer D; Horwitz SB; Wilson L; Briand C; Jordan MA
    Cancer Res; 2004 Jul; 64(14):4957-64. PubMed ID: 15256469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
    Edelman MJ; Quam H; Mullins B
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):141-4. PubMed ID: 11561780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulforaphene-Carboplatin Combination Synergistically Enhances Apoptosis by Disruption of Mitochondrial Membrane Potential and Cell Cycle Arrest in Human Non-Small Cell Lung Carcinoma.
    Chatterjee S; Rhee YH; Ahn JC
    J Med Food; 2016 Sep; 19(9):860-9. PubMed ID: 27467015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocimum sanctum induces apoptosis in A549 lung cancer cells and suppresses the in vivo growth of Lewis lung carcinoma cells.
    Magesh V; Lee JC; Ahn KS; Lee HJ; Lee HJ; Lee EO; Shim BS; Jung HJ; Kim JS; Kim DK; Choi SH; Ahn KS; Kim SH
    Phytother Res; 2009 Oct; 23(10):1385-91. PubMed ID: 19277950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides.
    Pešić M; Banković J; Aljančić IS; Todorović NM; Jadranin M; Vajs VE; Tešević VV; Vučković I; Momčilović M; Marković ID; Tanić N; Ruždijić S
    Food Chem Toxicol; 2011 Dec; 49(12):3165-73. PubMed ID: 21996302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin.
    Branco H; Oliveira J; Antunes C; Santos LL; Vasconcelos MH; Xavier CPR
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy.
    Hatakeyama Y; Kobayashi K; Nagano T; Tamura D; Yamamoto M; Tachihara M; Kotani Y; Nishimura Y
    Cancer Lett; 2014 Feb; 343(1):74-9. PubMed ID: 24139969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo.
    Nishizaki M; Meyn RE; Levy LB; Atkinson EN; White RA; Roth JA; Ji L
    Clin Cancer Res; 2001 Sep; 7(9):2887-97. PubMed ID: 11555607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
    von Pawel J; Harvey JH; Spigel DR; Dediu M; Reck M; Cebotaru CL; Humphreys RC; Gribbin MJ; Fox NL; Camidge DR
    Clin Lung Cancer; 2014 May; 15(3):188-196.e2. PubMed ID: 24560012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.